{"name":"Endeavor Biomedicines, Inc.","slug":"endeavor-biomedicines-inc","ticker":"","exchange":"","domain":"endeavorbiomedicines.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPTm92WHd4dERad1lqOWtwZTRTMUl6Q1M4cUJDNmZoUGlIQ3lDaVBNR2VlMGpnejJLTGlOb3ZOZlc1Uk1XRWZtWXRhMlFBVkFibExrb2h6Mm5XMDByMUYzMndlUC1GVzg0OENsZ2pLTzFybEg4OWt6eTJZTVhOT0ZCVHBfYVlyZTFsZnFERVVhUEZXaVNGMUU1NjlnWGk?oc=5","date":"2026-03-25","type":"trial","source":"openPR.com","summary":"Neuroblastoma Clinical Trial Pipeline Appears Robust With 50+ - openPR.com","headline":"Neuroblastoma Clinical Trial Pipeline Appears Robust With 50+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQcTkxeXNwTXMxWFljZXNaY3BkNFhjLWZ6MFgtUEtEVm1zWU9UbHFtSGFEX0swQ0pUVS1xV29ULWNsdGdxUG5LNnV2N1I1MmZXSVdHUnNiVGMyN3ozZzBVcEFBQXpkeF9PWHJ3UUNBS21qdjZFcG44eW1GLU9RVnVUbFpVYndNWVZ3aEEzMXNwNFFjTHRoQnN1TW1xLTJORF8xT0p3X0QzSDd5RzVacUNvNG9aQVFsNFNYTmlhWFhLZ25rQQ?oc=5","date":"2026-03-06","type":"pipeline","source":"BioCentury","summary":"A pulmonary fibrosis proof-of-concept wave puts antifibrotic progress within reach - BioCentury","headline":"A pulmonary fibrosis proof-of-concept wave puts antifibrotic progress within reach","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxOdm90RzFBMHJuOEwya29VbGhyb2dLMTRscWFmSzdjN0F2LVpGMENiYVE5MXZRbXIxdVNJMU84VXdQY04yREFZbkE4QmVjdlkxTVZEZzdSSF9xYzF1SGl4aDBRV2N3OW9qNU5uNzFRa09LZUJkWWVrQlJ0VHVPR0dnMFRmMDBQOF82ZTlKak94WUhCelhNeFFIa0ZkdlhzUHl4c3VEUlotWUxiMmxnNndhQUY2QVQ4TWxMeTRycTFIbFFqVlpMcHg3b0IwUE9Ya19hSmUwaElxaGdNWDNDRk5CVUxzb0N3R3p5dXQ1c21sanYzYXhWSmpJenkwUGxqUHRMTlpDMy1JYl9KV3B2dTZtU29kdzg4LXNaLXNWRkdGemZoa19pQTQ5aWlNbE50MmZwMFhfdlduZ3VlZVZ1Qk1WaV9VcVBLal9JaWN5U2VwMFdVLUl0?oc=5","date":"2026-02-26","type":"regulatory","source":"Barchart.com","summary":"Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics ","headline":"Pulmonary Fibrosis Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsig","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxOb2FpNnlvQ2NMX0ZSTnZkdGtFUXhFUzhyRXA4SjJQcF9uOHZRaWJDZ1hDUnZ0T0pLWmthYWRmM2NGTVNDZkFOQnZPbFlhY0lNUnJmNkpnYll3eERNOW8wVS1VMFV2QnE5bWMzZDBFcGduUUpqaDBpZGtSNlE1SDVDRTMxNENyMFJud3F0S3pyUi1rMHZhZ1JhUHNtc1VScWZoZkszc0lMYVFOaWhpUk5QMVhtbl92VU9WWlJnR2VwSnp5elhiV1hENHVXV0FpemhUa29jd0JxUGJqWnVFcTZ2dnAxWDQ4LTN4T3pyZ0xIcWtJdFk3dFVqaEp2cng2b0lSOTd0YTVQNGFXMzZteTA0N3VpbDg0U3dDT2J2QVliNGdPUldNa0Zndi1mRzZ3a3h1dHc?oc=5","date":"2026-02-09","type":"trial","source":"GlobeNewswire","summary":"Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline - GlobeNewswire","headline":"Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxPeG1TeHR3emVZcktqYl9vQmIxWjRzMVNaOFNRc0lmWnVnMEVKU2loWjJkM0RhUFItZ0VFcTdyX095dXhoMVlXU1F0Q0QySzJMcjU0bjNEWXB3RldBM2VTNmhpemxIUHg0Si1ESHRxVWdtelN5VXNQWFBaWUl4ZVNPVnVzSHpRWncxZ2tnU0pMekNBc2RlUTF6VXRhY1N4cEVLWmt5TEFoMXJDTEhOMjJWaHVrZ0JTSHZMVW5Jcko4NHJTTFpGbHl6a3U1QTByNlJnZVRYcFI1blo0eG9felB4SE1UVEp2UnQxY1dud1JWbWFTOTYyekwzblNNRkh2OFZ0Tmc?oc=5","date":"2025-11-03","type":"pipeline","source":"Barchart.com","summary":"Neuroblastoma Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight - Barchart.com","headline":"Neuroblastoma Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | De","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxOZnY1RWM3aTB6MXcwOUV1LUlvT2JiV2NHTkN2YU1XOFVnZWhTT3UyOHlBWU0tekY2cW9JUjZUNVBobHUtYnlBWkNSMlY5V0hodmtfWGl6UmtIWHk4amRMd1NhaFVicndYSHF6cUtvSWV4cm5zLUNGSXhrNWtWemJIWXdtd2lubTdPY1NLQU92eVBZb0xYRmxpTnVtQktWYnpkM1FlVl84M0RjMWY1eXRXNkF3dFZzQVZhblg2TEdleVU3bzNmQjVCSFdfOWRLMGlvMHhZbEdiS0s4VTc5S0k4RlN0SlRzaTYweXFKQkJ1OUpxTHJubVFPMGkxVDN3Y3RNX1lQcFkxNVlBUFp4SmljaW02bDFFNkZuUWR3c05UZDFIaXhpeXVYWFcyTWFJWC1ydE53a3oyVmxUWWh0Y0JIaHowZUlQSzRyRndTcUpKQ0tzdWNy?oc=5","date":"2025-09-30","type":"trial","source":"BioSpace","summary":"Endeavor BioMedicines Announces Publication of Positive Data from Phase 2a Trial in The Lancet Respiratory Medicine Evaluating taladegib (ENV-101) in Individuals with Idiopathic Pulmonary Fibrosis - B","headline":"Endeavor BioMedicines Announces Publication of Positive Data from Phase 2a Trial in The Lancet Respiratory Medicine Eval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxQNzJyREN6bWFscnpCR0lyVXJqWm5pTnBISmlhRV9UVUtHV1VvTUF6Snl4OTZWR0tQZlRkYUh4MzNOQzRTNENaSXBtZ1lqbC1ScjJmQVlNQjRXZmp0Ul9VV2lNanJVSllhRE9md3JRTHpXdDVXT0k2dWwwY2EweFJQalhmekF1SkVkVnZubW53dHV3NWJBVEJFLU1WbnRtVVpVTkN2NzVHR191Y1dydE1uX3R4dHZEaWxZWlo4bVVReFEteEJIMktzdmdhX19OYW1WSzF2ZHY3S08tWDg2OGI0bEp6SG50bDg3emU5Q2dpcGpoZ01JQ2tKMXp3S1EwMkpjT2d0d1VTa0FuWkEyM20tU3V1bTcyLTZYdi1zZUVVOER3ZDJOMHp2aUpsOC1GUUhRQ0lhdGFfQjV0X1hWZTFHS2tGZ19VVDJJQVFpd2NZX1FILXc?oc=5","date":"2025-07-16","type":"pipeline","source":"BioSpace","summary":"Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis - B","headline":"Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commissio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxQMk1CYm0tMjVHNWZ2WlhwR2FjRXhVM19IOWFWOGh0VmJMQlJ0T2RzNjdfUjBiMWhaVHRlLU9MVzJYZlpNbTJ5Q2JCNjltUnBlYlJCVGJCT25ReENGc3V4dzZ6UDh0bmE1S3NzcmlqcENtaE5oOWJvM1dyVVJPQUtXUHRlcmZtYjFGa3VLUGVmUFd2WlFqRU5na1VUU1BEa09oNWVhRzg3QTAzaVgybUFvUi10YjRxY2VPX0FnVkJTZDk5SmkxZlFyMGhhTjY0aTdKaWN6bXFRbWZpeXVhYWgxYVA2bTVUQ1ZfTnppLVZNcy01X3o1ZE03SkcwZHdtYk1aMkR6RQ?oc=5","date":"2025-05-01","type":"pipeline","source":"Business Wire","summary":"Endeavor BioMedicines Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference - Business Wire","headline":"Endeavor BioMedicines Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxObm9VSU9sOWFIemFwQlozQXR4N2VJOVBlTDNNWmdZSHlPTjZaYzhkM2szVVh4MU55MUh1dWx1S2J5dHBreXY3WWJNVkNqVEh4S2RXZEp4WHRmTTNwV1ZrN0xEV240TW9nVnk3S1RFYkcxM0lydUNMX2JCN1ROanhuQWJ3bEdHTHpIcV9Gek9RVlVuV0FJOGZ3LXRoZzN2QjRsT3RsTzNBdDVHYlhsSG9ZZDVyRmFNUnJDa0MtUmxTbkI3N1VGcjdxNWdyN1puckRDSXQyMGdmaFVnYlRUd2h3UG9TWWRkNlBhMHo5MkhSLVNvTWhKYVFZ?oc=5","date":"2024-06-12","type":"pipeline","source":"2 Minute Medicine","summary":"Endeavor BioMedicinesENV-101 (Taladegib): A Safe and Efficacious Disease-Modifying Agent In Treatment of Idiopathic Pulmonary Fibrosis - 2 Minute Medicine","headline":"Endeavor BioMedicinesENV-101 (Taladegib): A Safe and Efficacious Disease-Modifying Agent In Treatment of Idiopathic Pulm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPSkE2YjRoMkRRMzFnRWVLZ1JPU2dIQUN3cG9BRy1ISHV3VFdiM21DXzNRT01ucGFDVnJETEJYSWMxV1paMXJqWlZLVlJ2QmxrLXlTSlNNVFo2SkQ5SHZjNTdwdTh1cndCdDdVYTMtR08tRHFBeVQ3elhOZlpfaVh4UHJzVWFOVFoxRTBTVUhDM1VzZFk3Vk9MS21xUmprQXhSR3FhajBIWm1mZW05VEE?oc=5","date":"2024-04-24","type":"pipeline","source":"BioPharma Dive","summary":"Endeavor pulls in $132M to back cancer, lung disease drugs - BioPharma Dive","headline":"Endeavor pulls in $132M to back cancer, lung disease drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxOZHI5NzBTMUZIWlNwRGxiRy1waGJoNEhRTVpsWWZ2aW1xZ1pCNkNkeGZ2TGZ5Vk0yR01lNDRFa212UEFITVRyVC1pTHpmbm11ZG9mUUdoUUNnSzdrZU8wOGJqY3Q3UG81c0Z1Q2YyTkRQR0hrYVpQMFMzbTJ2NzQzWmd3OTRVcmRKQ0t1NjZYTXByVWxjcWhCMkUyMFR1cW9oaUlmWFo4b1RSS2xtRjJ5SXQ4VGxkMVdkMl95TVlSWmh2RjVBeFd1eE9JNnVFN1dFWDU4cXE1a3B3RFRFWTJOVDY1ODhnT0daNFhHNXJfRC0yYjd5U2lyb0lQd1NkUTIyaFlYVDlVSFQzNWNtWldSYjRWWXVzRkFDdE1XTHBVcUZtb0RLUXQxRng1NmtKYXN5aUkzUDhoQkNzV3pOVUNxX2ljVUVsdGlwRktCNw?oc=5","date":"2023-10-19","type":"deal","source":"PR Newswire","summary":"Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC) - PR Newswire","headline":"Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Gene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQTlJFNUhfX2RkSmUtRVlORTJPTzcyUm94cFhpNjhCRzFSTmNqREV0aFp6dE8wLWV6aHhySXJhek00ZU5fbWJOUzQ3MGVJRWtKSlFTbWdDcmQtT3k3ellGSFpWcTBIUEdPTTU2dF9pcF9BaV9adDRnRWFVUzZGUy1qTl8wNS1pQ3Z0Y0EyRno2MmMzVHZPQjF4N1hLeU85RkpQRU9YcG5pbGdLdnBwQWV0T3N3?oc=5","date":"2023-10-19","type":"deal","source":"Fierce Biotech","summary":"Hummingbird's HER3-targeted ADC entices Endeavor to sign $430M licensing deal - Fierce Biotech","headline":"Hummingbird's HER3-targeted ADC entices Endeavor to sign $430M licensing deal","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}